查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006274

獸藥市場：2026-2032年全球市場預測（依產品類型、疾病類型、目標動物、劑型、給藥途徑及最終用戶分類）

Livestock Medicine Market by Product Type, Disease Type, Animal Type, Formulation, Route of Administration, End Users - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，畜牧藥品市場價值將達到 208.2 億美元，到 2026 年將成長至 219.5 億美元，到 2032 年將達到 307.2 億美元，複合年成長率為 5.71%。

主要市場統計數據
基準年 2025 208.2億美元
預計年份：2026年 219.5億美元
預測年份 2032 307.2億美元
複合年成長率 (%) 5.71%

對當前趨勢和影響全球畜牧藥品市場的關鍵促進因素進行全面深入的洞察。

近年來，獸藥產業經歷了顯著的變革，這主要受全球對動物性蛋白質需求不斷成長、抗生素抗藥性監管要求日益嚴格以及生產效率提升的推動。隨著畜牧業規模的擴大以滿足消費者需求，生產者和獸醫面臨越來越大的壓力，他們需要採用先進的治療方法，既要保障動物健康，又要維護公眾安全。此外，藥物製劑和給藥系統的持續創新也拓展了治療選擇的範圍，以應對包括細菌感染疾病、寄生蟲感染和代謝紊亂在內的各種健康挑戰。

重新定義畜牧業健康管理策略，探索推動獸醫學創新的關鍵變革因素。

過去十年，獸醫學的格局因一系列變革性因素而重塑，這些因素的影響遠超傳統的藥物創新。精準畜牧技術已成為現代畜群健康管理的基石，透過即時監測生理指標和環境狀況，能夠主動預防健康威脅。同時，數位平台和雲端分析技術的融合，為獸醫和畜牧養殖戶提供了數據驅動的決策工具，從而能夠進行更精準的干涉並最佳化治療方案。

評估 2025 年美國對牲畜藥品和貿易進行關稅調整所帶來的連鎖經濟和營運影響。

美國於2025年實施的新關稅措施對獸藥的整個供應鏈和定價結構產生了一系列連鎖反應。關鍵活性成分和成品進口關稅的提高推高了國內製藥企業的生產成本，迫使它們尋求替代採購管道並與供應商重新談判合約。因此，歐洲和亞洲的區域製造地已成為籌資策略的關鍵樞紐，前置作業時間和物流韌性成為採購團隊的核心考量。

多方面的細分洞察，揭示了產品類型、疾病類型、動物種類、劑型和最終用戶的不同需求模式。

為了解獸藥市場的廣泛性，有必要詳細檢視各個細分維度的需求分佈。每個維度都反映了獨特的治療需求和應用場景。從產品類型來看，抗發炎藥、抗生素、驅蟲藥、飼料添加劑、荷爾蒙以及各種疫苗是市場的主要支柱。抗生素產品包括頭孢菌素類、青黴素類和四環黴素，抗寄生蟲藥物涵蓋了體內外寄生蟲控制劑。同時，飼料添加劑以益生元和益生菌製劑為主，激素分為促進生長激素和促生殖激素，疫苗技術則包括去活化疫苗、減毒活病毒疫苗和次單位疫苗。

美洲、歐洲、中東和非洲以及亞太地區獸藥引進趨勢和市場動態的區域差異分析

區域趨勢在獸藥產品組合的建構中發揮著至關重要的作用，經濟狀況和監管環境的差異決定了藥物的普及率和治療重點。在美洲，北美和南美強大的生產體係日益支持精準醫療方法的推廣應用，這得益於對數位醫療基礎設施的大量投資以及先進的抗菌藥物合理使用政策。跨境貿易協定和區域協調努力進一步擴大了先進動物醫藥的可及性，並創造了一個以產品快速上市和合作研究為特徵的競爭舉措。

分析推動畜牧治療領域競爭優勢和技術進步的產業先驅和策略合作夥伴關係。

在競爭激烈的市場環境中，一些產業相關人員正透過強大的研發開發平臺和策略合作夥伴關係來強化其治療產品組合，從而脫穎而出。全球領先的獸藥公司正利用生物技術和數位健康領域的跨學科專長，開發新一代疫苗、長效製劑和精準給藥平台。同時，一些專注於特定領域的生物技術企業正尋求透過專注於抗寄生蟲生技藥品和基於微生物組的飼料添加劑等細分市場來打開市場。

為畜牧業健康產業的領導者提供切實可行的策略建議，以實現永續成長和市場主導。

為了在不斷變化的市場環境中蓬勃發展，行業領導者應優先投資於數位健康基礎設施和精準動物飼養解決方案。增強的即時監測能力和數據分析框架能夠實現更積極主動的疾病管理，從而減少藥物浪費並改善動物福利。同時，建立包含疫苗和益生菌等替代療法的綜合抗菌藥物管理方案，有助於加強監管合規性和公眾信任。

本報告詳細介紹了構成本報告基礎的嚴謹調查方法，包括資料來源、分析架構和檢驗技術。

本報告基於嚴謹的調查方法，整合了二手數據和一手數據，以提供全面可靠的分析。二手研究包括對科學論文、政府法規、行業白皮書和公開的企業資訊披露進行廣泛審查，從而深入了解市場動態、技術趨勢和監管環境。

總結了關鍵發現和對相關人員在不斷變化的畜牧藥品和獸藥領域中應遵循的策略意義。

在不斷變化的法規環境、技術突破和消費者期望的推動下，獸醫學領域已開啟一個充滿活力的新時代。主要發現包括：數位健康解決方案的變革力量、合理使用抗生素的關鍵性，以及在關稅壓力下建立多元化價值鏈的策略必要性。此外，詳細的細分分析揭示了不同疾病類型、動物類別、製劑偏好和終端使用者群體對產品和服務的不同需求，凸顯了精準商業策略的價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：獸藥市場：依產品類型分類

  • 抗發炎藥
  • 抗生素
    • 頭孢菌素
    • 青黴素
    • 四環黴素
  • 殺蟲劑
    • 體外寄生蟲控制劑
    • 體內寄生蟲控制劑
  • 飼料添加劑
    • 益生元
    • 益生菌
  • 荷爾蒙
    • 生長激素
    • 生殖荷爾蒙
  • 疫苗
    • 去活化疫苗
    • 減毒活病毒疫苗
    • 次單位疫苗

第9章：獸藥市場：依疾病類型分類

  • 感染疾病
  • 代謝性疾病
  • 營養缺乏
  • 寄生蟲病
  • 生殖疾病

第10章：獸藥市場：依目標動物分類

  • 水產養殖
  • 牛
  • 山羊
  • 家禽
  • 羊
  • 豬

第11章：獸藥市場：以劑型分類

  • 膠囊
  • 凝膠
  • 液體
  • 粉末
  • 藥片

第12章：獸藥市場：依給藥途徑分類

  • 吸入
  • 注射藥物
    • 肌肉內部
    • 靜脈
  • 口服
    • 液體
    • 藥片
  • 外用
    • 奶油
    • 修補

第13章：獸藥市場：依最終用戶分類

  • 畜牧業的棋子
  • 動物診所
  • 動物醫院

第14章：獸藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：獸藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：獸藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國獸藥市場

第18章：中國獸藥市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Anicon Labor GmbH by SAN Group GmbH
  • AniCura Group by Mars Petcare
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Calier Laboratories SA
  • Ceva Sante Animale
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Inc.
  • HESTER BIOSCIENCES LIMITED
  • HIPRA SA
  • Indian Immunologicals Ltd.
  • Koninklijke DSM NV
  • Merck KGaA
  • Neogen Corporation
  • Norbrook Laboratories Ltd.
  • Parnell Pharmaceuticals Holdings Ltd.
  • Phibro Animal Health Corporation
  • Vetoquinol SA
  • Vetpharma Animal Health SL
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-FE3E5C0AE72F

The Livestock Medicine Market was valued at USD 20.82 billion in 2025 and is projected to grow to USD 21.95 billion in 2026, with a CAGR of 5.71%, reaching USD 30.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.82 billion
Estimated Year [2026] USD 21.95 billion
Forecast Year [2032] USD 30.72 billion
CAGR (%) 5.71%

Setting the Stage for Comprehensive Insights into the Current Dynamics and Key Drivers Shaping Livestock Medicine Markets Globally

In recent years, the livestock medicine sector has undergone a period of remarkable transformation driven by escalating global demand for animal protein, stringent regulatory requirements regarding antimicrobial resistance, and heightened focus on production efficiency. As livestock populations expand to meet consumption needs, producers and veterinarians alike are under mounting pressure to adopt advanced therapeutic interventions that ensure animal health while safeguarding public safety. Moreover, continuous innovation in pharmacological formulations and delivery systems has broadened the therapeutic toolkit available to address a spectrum of health challenges spanning bacterial infections, parasitic infestations, and metabolic disorders.

Moving forward, understanding the confluence of demographic shifts, policy frameworks, and scientific breakthroughs is critical for stakeholders seeking to navigate this dynamic environment. Analysts and decision-makers must consider how emerging disease threats, evolving animal husbandry practices, and sustainability imperatives intersect to shape investment priorities and commercial strategies. By providing a comprehensive overview of current market dynamics and emerging patterns, this executive summary lays the foundation for a deeper exploration of critical industry trends, regulatory influences, and segmentation nuances. Through a structured narrative, readers will gain clarity on the forces accelerating change, the areas of greatest opportunity, and the potential obstacles that may temper growth. This introduction sets the stage for a nuanced examination of transformative shifts, tariff impacts, segmentation insights, and strategic recommendations presented in subsequent sections.

Exploring the Major Transformative Forces Redefining Livestock Health Management Strategies and Driving Innovation Across Veterinary Medicine

Over the past decade, the livestock medicine landscape has been reshaped by a constellation of transformative forces that extend beyond traditional pharmaceutical innovation. Precision livestock farming technologies have emerged as a cornerstone of modern herd health management, enabling real-time monitoring of physiological indicators and environmental conditions to preemptively address health threats. Simultaneously, the integration of digital platforms and cloud-based analytics has empowered veterinarians and farmers with data-driven decision-making tools, fostering more targeted interventions and optimized treatment regimens.

In parallel, growing regulatory scrutiny around antimicrobial resistance has catalyzed the development of alternative therapeutics such as vaccines, probiotics, and novel antiparasitic agents. Breakthroughs in subunit and live attenuated vaccine formulations have significantly reduced the reliance on broad-spectrum antibiotics, while advancements in formulation science have improved bioavailability and compliance through innovative delivery mechanisms. Lastly, increasing consumer awareness of animal welfare and sustainable agriculture practices is driving demand for hormone-free feed additives and environmentally responsible pharmaceuticals, prompting industry stakeholders to redefine their research and development priorities.

Assessing the Cascading Economic and Operational Consequences of 2025 United States Tariff Adjustments on Livestock Pharmacy and Trade

The implementation of new tariff measures in 2025 by the United States has introduced a series of ripple effects throughout the livestock medicine supply chain and pricing structures. Heightened import duties on key active pharmaceutical ingredients and finished products have elevated production costs for domestic formulators, compelling manufacturers to explore alternative sourcing corridors and renegotiated supplier agreements. As a result, regional manufacturing hubs in Europe and Asia are emerging as critical pivot points for procurement strategies, with lead times and logistical resilience becoming central considerations for procurement teams.

Moreover, downstream distributors and veterinary service providers are experiencing compressed margins due to escalated acquisition costs, which in turn has triggered a reassessment of pricing models and inventory management practices. These shifts have also accelerated the exploration of local API production and co-manufacturing partnerships as viable cost-mitigation approaches. Although short-term disruptions have tested the adaptability of established supply chains, they have simultaneously fostered a climate of strategic collaboration between governments, research institutions, and private sector actors aiming to enhance domestic API capabilities and reduce tariff vulnerabilities.

Uncovering Multidimensional Segmentation Insights That Illuminate Varied Demand Patterns by Product Type Disease Type Animal Type Formulation and End User

Understanding the breadth of livestock medicine requires a closer look at how demand diverges across multiple segmentation dimensions, each reflecting distinct therapeutic needs and usage scenarios. From a product type perspective, anti-inflammatory agents, antibiotics, antiparasitic agents, feed additives, hormones, and a diverse array of vaccines serve as the core pillars of the market. Antibiotic offerings span cephalosporins, penicillins, and tetracyclines, while antiparasitic portfolios include both ectoparasiticides and endoparasiticides. Meanwhile, feed additives are enriched with prebiotic and probiotic formulations, hormones are classified into growth and reproductive categories, and vaccine technologies encompass inactivated, live attenuated, and subunit options.

When viewed through the lens of disease type, infectious diseases lead the therapeutic agenda, followed by targeted interventions for metabolic disorders, nutritional deficiencies, parasitic infestations, and reproductive ailments. Animal type segmentation underscores differentiated requirements across aquaculture operations, cattle ranching, goat herding, poultry facilities, sheep farms, and swine production systems. Formulation preferences range from capsules and gels to liquids, powders, and tablets, each tailored to stability and ease of administration. Route of administration insights further nuance treatment selection with inhalation therapies, injectable options subdivided into intramuscular and intravenous formats, oral solutions available as liquids and tablets, and topical applications delivered via creams and patches. Finally, end users such as livestock farmers, veterinary clinics, and veterinary hospitals each exert unique purchasing behaviors and service expectations, driving targeted commercial strategies across the value chain.

Analyzing Regional Variations in Livestock Pharmaceutical Adoption Trends and Market Dynamics Across Americas EMEA and Asia-Pacific Territories

Regional dynamics play a crucial role in shaping livestock medicine portfolios, with divergent economic landscapes and regulatory frameworks dictating adoption rates and therapeutic priorities. In the Americas, robust production systems in North and South regions are increasingly adopting precision medicine approaches, supported by substantial investment in digital health infrastructure and progressive antimicrobial stewardship policies. Cross-border trade agreements and regional harmonization efforts further amplify access to advanced veterinary pharmaceuticals, fostering a competitive environment marked by rapid product launches and collaborative research initiatives.

Across Europe, the Middle East, and Africa, stakeholders navigate a complex tapestry of regulatory requirements, ranging from stringent European Union directives on drug residues to rapidly evolving guidelines in emerging African markets. The push for sustainable livestock practices in Europe is driving demand for organic and residue-free alternatives, while Middle Eastern regions are leveraging public-private partnerships to bolster local manufacturing capabilities. Conversely, Asia-Pacific represents a growth engine fueled by expanding aquaculture and poultry operations, with countries such as China and India spearheading large-scale adoption of vaccines and antiparasitic agents. Evolving infrastructures, increasing veterinary service penetration, and government incentives for biosecurity measures are key factors accelerating market uptake across this diverse region.

Profiling Pioneering Industry Participants and Strategic Alliances Driving Competitive Advantage and Technological Advancement in Livestock Therapeutics

Within this competitive landscape, certain industry participants have distinguished themselves through robust R&D pipelines and strategic collaborations that enhance their therapeutic portfolios. Leading global animal health companies are leveraging cross-disciplinary expertise in biotechnology and digital health to develop next-generation vaccines, long-acting formulations, and precision administration platforms. At the same time, specialized biotech ventures are making inroads by focusing on niche segments such as antiparasitic biologics and microbiome-based feed enhancers.

Strategic alliances between pharmaceutical firms and contract research organizations are accelerating clinical trial execution, regulatory submissions, and post-market surveillance activities. This trend is complemented by partnerships with academic institutions that provide early-stage innovation, ensuring a steady flow of novel compounds and delivery technologies. Additionally, emerging players in regional markets are capitalizing on localized manufacturing advantages and tailored formulations to address endemic disease profiles, thereby carving out differentiated market positions. Collectively, these varied approaches are redefining competitive dynamics and underscoring the importance of agility, innovation, and collaboration in sustaining long-term growth trajectories.

Presenting Actionable Strategic Recommendations to Equip Livestock Health Industry Leaders with Practical Pathways for Sustainable Growth and Market Leadership

To thrive amid evolving market conditions, industry leaders should prioritize investment in digital health infrastructures and precision livestock farming solutions. Enhancing real-time monitoring capabilities and data analytics frameworks will enable more proactive disease management, reduce therapeutic waste, and improve animal welfare outcomes. Simultaneously, establishing comprehensive antimicrobial stewardship programs that incorporate alternative therapies such as vaccines and probiotics will strengthen both regulatory compliance and public trust.

Moreover, diversifying supply chain networks through strategic partnerships with regional manufacturers and contract API producers can mitigate tariff-related risks while enhancing operational resilience. Expanding into high-growth segments, including aquaculture and poultry, requires tailored product development and targeted marketing strategies that address specific disease profiles and end-user requirements. Finally, fostering collaborative research initiatives with academic and governmental agencies will accelerate the advancement of novel therapeutics, drive cost efficiencies in clinical development, and fortify the innovation pipeline for sustained competitive differentiation.

Detailing Rigorous Research Methodology Encompassing Data Collection Sources Analytical Frameworks and Validation Techniques Underpinning the Report

This report is grounded in a rigorous research methodology that synthesizes both secondary and primary data sources to deliver a comprehensive and reliable analysis. Secondary research encompassed an extensive review of scientific publications, government regulations, industry white papers, and publicly available company disclosures to establish foundational insights into market dynamics, technological trends, and regulatory landscapes.

Primary research efforts included structured interviews with senior executives, veterinary practitioners, supply chain managers, and end-user stakeholders, providing firsthand perspectives on current challenges, purchasing behaviors, and innovation priorities. Data validation processes involved cross-referencing reported financials, product launch announcements, and patent filings to ensure consistency and accuracy. Analytical frameworks such as SWOT analysis, PESTLE evaluation, and Porter's Five Forces were applied to contextualize competitive positioning, identify growth drivers and barriers, and project strategic implications without the inclusion of specific market sizing or forecasting figures.

Summarizing Key Findings and Strategic Implications for Stakeholders Navigating the Evolving Landscape of Livestock Medicine and Veterinary Care

The convergence of evolving regulatory environments, technological breakthroughs, and shifting consumer expectations has set the stage for a dynamic era in livestock medicine. Key discoveries include the transformative power of digital health solutions, the critical importance of antimicrobial stewardship, and the strategic necessity of diversified supply chains in the face of tariff pressures. Additionally, in-depth segmentation analyses reveal distinct product and service requirements across disease types, animal categories, formulation preferences, and end-user profiles, underscoring the value of targeted commercial strategies.

As regional markets continue to diverge in terms of regulatory rigor and infrastructural readiness, stakeholders must adopt flexible approaches that balance global best practices with local market realities. By integrating strategic partnerships, embracing innovation-driven collaborations, and reinforcing data-driven decision-making processes, industry participants can position themselves to capitalize on emerging opportunities while navigating potential disruptions. This executive summary has distilled the essential insights necessary to inform strategic planning and guide resource allocation, paving the way for more resilient and responsive operations in the livestock medicine sector.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Livestock Medicine Market, by Product Type

  • 8.1. Anti-inflammatory Agents
  • 8.2. Antibiotics
    • 8.2.1. Cephalosporins
    • 8.2.2. Penicillins
    • 8.2.3. Tetracyclines
  • 8.3. Antiparasitic Agents
    • 8.3.1. Ectoparasiticides
    • 8.3.2. Endoparasiticides
  • 8.4. Feed Additives
    • 8.4.1. Prebiotics
    • 8.4.2. Probiotics
  • 8.5. Hormones
    • 8.5.1. Growth Hormones
    • 8.5.2. Reproductive Hormones
  • 8.6. Vaccines
    • 8.6.1. Inactivated Vaccines
    • 8.6.2. Live Attenuated Vaccines
    • 8.6.3. Subunit Vaccines

9. Livestock Medicine Market, by Disease Type

  • 9.1. Infectious Diseases
  • 9.2. Metabolic Diseases
  • 9.3. Nutritional Deficiency Diseases
  • 9.4. Parasitic Diseases
  • 9.5. Reproductive Diseases

10. Livestock Medicine Market, by Animal Type

  • 10.1. Aquaculture
  • 10.2. Cattle
  • 10.3. Goats
  • 10.4. Poultry
  • 10.5. Sheep
  • 10.6. Swine

11. Livestock Medicine Market, by Formulation

  • 11.1. Capsules
  • 11.2. Gels
  • 11.3. Liquids
  • 11.4. Powders
  • 11.5. Tablets

12. Livestock Medicine Market, by Route of Administration

  • 12.1. Inhalation
  • 12.2. Injectable
    • 12.2.1. Intramuscular
    • 12.2.2. Intravenous
  • 12.3. Oral
    • 12.3.1. Liquids
    • 12.3.2. Tablets
  • 12.4. Topical
    • 12.4.1. Creams
    • 12.4.2. Patches

13. Livestock Medicine Market, by End Users

  • 13.1. Livestock Farmers
  • 13.2. Veterinary Clinics
  • 13.3. Veterinary Hospitals

14. Livestock Medicine Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Livestock Medicine Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Livestock Medicine Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Livestock Medicine Market

18. China Livestock Medicine Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Anicon Labor GmbH by SAN Group GmbH
  • 19.6. AniCura Group by Mars Petcare
  • 19.7. Biogenesis Bago SA
  • 19.8. Boehringer Ingelheim International GmbH
  • 19.9. Calier Laboratories S.A.
  • 19.10. Ceva Sante Animale
  • 19.11. Dechra Pharmaceuticals PLC
  • 19.12. Elanco Animal Health Inc.
  • 19.13. HESTER BIOSCIENCES LIMITED
  • 19.14. HIPRA S.A.
  • 19.15. Indian Immunologicals Ltd.
  • 19.16. Koninklijke DSM N.V.
  • 19.17. Merck KGaA
  • 19.18. Neogen Corporation
  • 19.19. Norbrook Laboratories Ltd.
  • 19.20. Parnell Pharmaceuticals Holdings Ltd.
  • 19.21. Phibro Animal Health Corporation
  • 19.22. Vetoquinol S.A.
  • 19.23. Vetpharma Animal Health S.L.
  • 19.24. Virbac SA
  • 19.25. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LIVESTOCK MEDICINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LIVESTOCK MEDICINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES LIVESTOCK MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA LIVESTOCK MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PREBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PREBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PREBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PROBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PROBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PROBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROWTH HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROWTH HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY METABOLIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY METABOLIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY NUTRITIONAL DEFICIENCY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY NUTRITIONAL DEFICIENCY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY NUTRITIONAL DEFICIENCY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PARASITIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PARASITIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PARASITIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REPRODUCTIVE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GOATS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GOATS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GOATS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SHEEP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SHEEP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SHEEP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVESTOCK FARMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVESTOCK FARMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY LIVESTOCK FARMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 170. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 171. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 172. AMERICAS LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPE LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 278. GLOBAL LIVESTOCK MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 290. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 291. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 292. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 293. ASEAN LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. GCC LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. GCC LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 297. GCC LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 298. GCC LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 300. GCC LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 301. GCC LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. GCC LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. GCC LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 304. GCC LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 305. GCC LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 306. GCC LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 307. GCC LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 308. GCC LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 316. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 320. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 322. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION LIVESTOCK MEDICINE MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY ANTIPARASITIC AGENTS, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY FEED ADDITIVES, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 331. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 332. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 334. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 335. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 336. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 337. BRICS LIVESTOCK MEDICINE MARKET SIZE, BY TOPICAL, 2018-2032